ESMO 2023 special: Prof. Powles shares positive KEYNOTE-A39 trial results

In this special podcast, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talks with Prof. Thomas Powles (GB) about the positive results of the EV-302/KEYNOTE-A39 trial that were announced at ESMO 2023.

Published Sun, 22 Oct 2023
PodcastBladder CancerEAU GuidelinesESMO 2023ESMO

Prof. Powles shares details on the rationale and design of the EV-302/KEYNOTE-A39 study: an open-label, randomised, controlled, phase 3 study evaluating enfortumab vedotin in combination with pembrolizumab (EV+P) versus chemotherapy in patients with previously untreated locally advanced metastatic urothelial carcinoma (la/mUC).

The dual endpoints of this trial are overall survival (OS) and progression-free survival (PFS) per RECIST (response evaluation criteria in solid tumours) v 1.1 by blinded independent central review (BICR).

Prof. Powles: "The topline results from the EV-302/KEYNOTE-A39 trial are encouraging for patients with advanced-stage urothelial cancer, which is aggressive and associated with devastating outcomes."

For more details on this study, you can read the abstract on the UROONCO Bladder Cancer educational platform.

For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, Google Podcasts.